Antimicrobial Drug News and Research

RSS

Antimicrobials are substance that kills microorganisms such as bacteria or mold, or stops them from growing and causing disease.

Biomedical scientists identify set of genes essential for A. baumannii gram-negative bacteria

Biomedical scientists collaborating on translational research at two Buffalo institutions are reporting the discovery of a novel, and heretofore unrecognized, set of genes essential for the growth of potentially lethal, drug-resistant bacteria.

15 Sep 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Nanosphere receives FDA marketing approval for Verigene GP Blood Culture Nucleic Acid Test

The U.S. Food and Drug Administration today allowed marketing of the first nucleic acid test that can identify 12 different bacterial types known to cause bloodstream infections.

28 Jun 2012

Allergy risk in children linked to antibacterials in personal-care products

Exposure to common antibacterial chemicals found in soap, toothpaste, mouthwash and other personal-care products may make children more prone to a wide range of food and environmental allergies, according to new research from Johns Hopkins Children’s Center.

19 Jun 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

AVMA warns against further restrictions on cephalosporin usage in food animals that are not backed by science

The American Veterinary Medical Association (AVMA) announced today that the FDA's order prohibiting certain uses of cephalosporins in food animals appears consistent with the current AVMA position on the limited prohibition on extra-label drug use, but warned against further restrictions not backed by science.

7 Jan 2012

Antibiotic-resistant Salmonella worries experts

According to an international team of researchers a strain of Salmonella that is resistant to important antibiotics has spread from Africa to Europe in recent years and has been spotted in a few samples of imported spices in the United States.

4 Aug 2011

Drug resistant gonorrhea discovered

Japanese scientists have found a superbug strain of gonorrhea that’s resistant to all available antibiotics. This can pose a threat to public health worldwide, infectious disease experts say.

11 Jul 2011

Lytix Biopharma completes two LTX-109 Phase I/IIa studies in MRSA, Gram+ skin infections

The Norwegian pharmaceutical company Lytix Biopharma today announces the successful completion of two Phase I/IIa studies with the topical antimicrobial drug Lytixar - one for nasal decolonisation of MRSA / MSSA bacteria and one for treatment of Gram+ skin infections.

26 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

Marking World Health Day, WHO warns misuse of antibiotics undermining global fight against infectious diseases

U.N. officials on Thursday marked World Health Day with a warning that "the misuse and irrational use of antibiotics has undermined the global fight against tuberculosis and malaria, warning of a possible return to the days before the drugs were developed," and called for urgent action to control the spread of drug resistance, Reuters reports.

8 Apr 2011

Hospira focuses on clinical surveillance systems to help reduce antimicrobial resistance

As part of World Health Day 2011, the World Health Organization is calling on policy makers, providers, the public and the healthcare industry to take action to combat the serious health threat of antimicrobial resistance.

8 Apr 2011

Experts welcome World Health Day on antibiotic resistance as timely

The European Society of Clinical Microbiology and Infectious Diseases (ESCMID) welcomes the focus on drug resistance for this year’s World Health Day as it is an issue that the Society has been proactively working on for the past 25 years.

6 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

Disinfectant hand gels not effective against Swine flu: Study

According to the latest research published this Sunday, regular use of alcohol-based disinfecting hand gels has little effect on the H1N1 swine flu infection rates. The authors of the study said that the infection is spread by air droplets rather than touch and contact.

12 Sep 2010

Lytix Biopharma granted Hungarian approval for Lytixar Phase IIa clinical trial in Gram positive skin infections

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa clinical trial with Lytixar (LTX-109) treatment of skin infections caused by Gram positive bacteria.

2 Sep 2010

Lytix Biopharma receives approval to initiate Phase I/IIa clinical trial of Lytixar for MRSA

The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency to commence a Phase I/IIa clinical trial with Lytixar (LTX-109) for nasal decolonisation of MRSA.

24 May 2010

Lytix Biopharma AS receives approval to commence Phase I clinical trials of Oncopore

The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.

15 Dec 2009

bioMerieux announces the upcoming availability of ABxAlert from ICNet International

bioMerieux, a world leader in the field of in vitro diagnostics, announced the upcoming availability of ABxAlert® from ICNet International Ltd., a global clinical informatics company, at the 44th American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition.

8 Dec 2009